|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
156,320,000 |
Market
Cap: |
6.57(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.26 - $43.27 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
Total People Bought |
0 |
0 |
6 |
6 |
Total Buy Transactions |
0 |
0 |
6 |
7 |
Total Shares Sold |
150,000 |
332,056 |
611,027 |
1,200,893 |
Total Sell Value |
$6,225,080 |
$13,395,200 |
$21,003,717 |
$39,590,443 |
Total People Sold |
1 |
8 |
8 |
10 |
Total Sell Transactions |
3 |
20 |
27 |
48 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bain Capital Partners Xii, Llc |
10% Owner |
|
2023-10-16 |
4 |
B |
$22.81 |
$124,999,986 |
I/I |
5,480,052 |
65,679,781 |
1.5 |
77% |
|
Edelman Joseph |
Director |
|
2023-10-16 |
4 |
B |
$22.81 |
$19,999,990 |
I/I |
876,808 |
10,794,876 |
2.1 |
77% |
|
Coles N Anthony |
|
|
2023-09-07 |
4 |
AS |
$24.07 |
$1,203,415 |
D/D |
(50,000) |
2,704 |
|
76% |
|
Coles N Anthony |
|
|
2023-09-07 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Burgess Paul D. |
See Remarks |
|
2023-08-04 |
4 |
B |
$22.93 |
$501,794 |
D/D |
21,880 |
21,880 |
0.01 |
83% |
|
Renaud Ronald C Jr |
President & CEO |
|
2023-08-03 |
4 |
B |
$23.96 |
$2,008,811 |
I/I |
83,857 |
83,857 |
0.01 |
73% |
|
Coles N Anthony |
|
|
2023-07-11 |
4 |
AS |
$30.03 |
$1,501,340 |
D/D |
(50,000) |
2,704 |
|
-20% |
|
Coles N Anthony |
|
|
2023-07-11 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Bain Capital Partners Xii, Llc |
10% Owner |
|
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
|
- |
|
Dekkers Marijn E |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
31,822 |
|
- |
|
Koppel Adam |
Director |
|
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
|
- |
|
Koppel Adam |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
Patrick Deval L |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
Riedel Norbert G |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
46,092 |
|
- |
|
Giordano Douglas E. |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
Mckernan Ruth |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
Gordon Christopher R |
Director |
|
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
|
- |
|
Gordon Christopher R |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
Greene Gabrielle E |
Director |
|
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
47,853 |
|
- |
|
Bodenrader Mark |
See Remarks |
|
2023-06-02 |
4 |
AS |
$32.95 |
$62,440 |
D/D |
(1,895) |
5,522 |
|
-32% |
|
Bodenrader Mark |
See Remarks |
|
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,733 |
7,417 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-06-01 |
4 |
AS |
$32.60 |
$1,630,070 |
D/D |
(50,000) |
2,704 |
|
-30% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-06-01 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-05-04 |
4 |
AS |
$31.36 |
$1,573,434 |
D/D |
(50,000) |
2,704 |
|
-28% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-05-04 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
120 Records found
|
|
Page 3 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|